Thank you for your interest! Unfortunately this offer has ended.
For the latest deals and promotions, please sign up for our email newsletter below, or contact us now!
Sitemap
- About Us
- Gene Editing
- Animal & Cell Models
- Animal Models
- Humanized Immune-Checkpoint Mice
- Humanized Cytokine Mice
- Humanized GPCR Mice
- Other Humanized Models
- Immunodeficient Mice (B-NDG background)
- Immunodeficient Mouse Models (Non B-NDG background)
- Reporter Models
- Cre Mouse/Rat Models
- DTR Models
- Other Tool Models
- Disease Mouse Models
- Drug Target Knockout Mouse Models
- Other Knockout Mouse Models
- Cell Lines
- Animal Models
- Efficacy & Toxicity Studies
- Inflammatory Disease Modeling
- Psoriasis Model
- Atopic Dermatitis Model
- Delayed type hypersensitivity model
- Acute Lung Injury & Inflammation Models
- Asthma Model
- Bleomycin-Induced Pulmonary Fibrosis Model
- Rheumatoid Arthritis Model
- Ovariectomy (OVX) induced Osteoporosis Model
- Osteoarthritis Model
- EAE Model
- LPS Mouse Model of Acute Inflammation
- Inflammatory Bowel Disease Model
- Systemic Lupus Erythematosus Model
- 5/6 Nephrectomy Chronic Kidney Disease Model
- Metabolic Disease Modeling
- NASH Mouse Models
- High-fat diet-induced obese (DIO) mouse model
- Spontaneous diabetes model
- STZ model
- Bile duct ligation-induced liver fibrosis Mouse Model
- TAA (Thioacetamide) -induced liver fibrosis Mouse Model
- Acetaminophen-induced Liver Injury Model
- Concanavalin A hepatitis model
- Atherosclerosis model
- In Vivo Pharmacology Services
- PK/PD Assays & In vitro Pharmacology Studies
- Efficacy & Toxicity Case Studies
- Inflammatory Disease Modeling
- RenMice™ Platforms
- Preclinical & Clinical Assets
- Antibody Hits Library
- Agonistic anti-CD40 IgG2 antibody YH003
- Anti-CTLA-4 IgG1 monoclonal antibody YH001
- Anti-OX40 IgG1 antibody YH002
- Agonistic anti-4-1BB IgG1 antibody YH004
- Anti-PD-1 x CD40 bispecific antibody YH008
- HER2 x TROP2 bispecific ADC YH012
- Antagonistic anti-CD40 fully human antibody YH015
- Careers
- News & Resources
- Investors
Product Categories
- Cre Mouse/Rat Models
- Drug Target Knockout Mouse Models
- DTR Models
- Humanized Cytokine Mice
- Humanized GPCR Mice
- Humanized Immune-Checkpoint Mice
- Humanized Tumor Cell Lines
- Immunodeficient Mice (B-NDG background)
- Immunodeficient Mouse Models (Non B-NDG background)
- Other Cancer Cell Lines
- Other Knockout Mouse Models
- Other Tool Models
- Reporter Models
Events
- Join Us at PEGS Boston 2024 | April 26, 2024
- Check Out Our CD40 mAb Phase II Poster at ASCO2024! | April 25, 2024
- Join us at Booth D23 at BIO KOREA 2024! May 8-10 | April 23, 2024
- Immuno-Oncology Summit Europe 2024: April 23-25 | April 11, 2024
- Festival of Biologics USA 2024: April 15-17 | April 11, 2024
- Webinar: Empowering Discovery and Development of Bispecific ADCs With a Common Light Chain Antibody Library and a Novel Linker/Payload | April 04, 2024
News
- April 2024 Newsletter | April 11, 2024
- Biocytogen’s Antibody Partner Syncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024 | April 09, 2024
- Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates | March 25, 2024
- Biocytogen Symposium 2024: New Targets, New Therapeutics | February 24, 2024
- Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement | February 20, 2024
- Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development | January 23, 2024
